Zipalertinib Combo Shows 6-Month PFS Benefit in Phase 3 REZILIENT3 — Full Data at WCLC
CGEM has more than doubled off its 52-week low of $5.68.
Summary
Full Phase 3 REZILIENT3 data show zipalertinib plus chemotherapy delivered a 6-month median PFS improvement (14.5 vs 8.5 months, HR 0.50) and higher response rates (65.0% vs 40.3%) in first-line EGFR exon 20 insertion NSCLC, presented at WCLC 2026.
Key Events · Product Development and Regulatory · CGEM
-
Phase 3 REZILIENT3 Full Data Presented
Zipalertinib plus chemotherapy achieved median PFS of 14.5 months vs 8.5 months for chemotherapy alone (HR 0.50, 95% CI 0.34-0.73, P=0.00015) in first-line EGFR exon 20 insertion NSCLC.
-
Response Rates and Duration
Objective response rate was 65.0% vs 40.3% (P<0.0001), with median duration of response of 14.2 months vs 9.9 months. Interim OS hazard ratio was 0.72 (95% CI 0.42-1.23) at 30% maturity.
-
Safety Profile Consistent
Grade ≥3 AEs occurred in 87.1% vs 54.4% of patients, primarily manageable hematologic events (58.6% vs 28.7%). No new safety signals observed; EGFR-related Grade ≥3 toxicities were infrequent.
-
WCLC Presidential Symposium
Data were featured in a Presidential Symposium at IASLC 2026 WCLC on September 14, 2026, highlighting the potential to change clinical practice in this patient population.
Analysis · CGEM · Life Sciences
The full Phase 3 REZILIENT3 dataset, presented at WCLC 2026, showed that zipalertinib plus chemotherapy extended median progression-free survival to 14.5 months versus 8.5 months for chemotherapy alone (HR 0.50, P=0.00015) in first-line EGFR exon 20 insertion NSCLC. Objective response rate was 65.0% versus 40.3% (P<0.0001), with a longer median duration of response (14.2 vs 9.9 months). The interim overall survival hazard ratio was 0.72 (95% CI 0.42-1.23) at 30% maturity. Safety showed higher Grade ≥3 AEs (87.1% vs 54.4%) but primarily manageable hematologic toxicities, with no new safety signals. These data support a potential first-line regulatory filing and position zipalertinib as a practice-changing option in this genetically defined NSCLC subset.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGEM was trading at $20.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.68 to $23.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.